Thursday, April 16, 2020

Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.

The vaccine will work by using bacteriophage, a process that will allow the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.

“When complete, our DNA-based vaccine will be administered non-invasively as a nasal spray that delivers nanomedicine engineered to immunize and decrease COVID-19 infections,” explains Roderick Slavcev, a professor in the School of Pharmacy who specializes in designing vaccines, pharmaceuticals and gene-therapy treatments. “This research combines the expertise of many and leverages existing technology developed by my team, which we’re reconfiguring for a COVID-19 application.”

Full article: [Waterloo Stories]

Note: This research has not yet been peer-reviewed and is being released as part of UWaterloo’s commitment to help inform Canada’s COVID-19 response.

  1. 2020 (4)
    1. June (1)
    2. April (1)
    3. March (2)
  2. 2019 (11)
    1. November (2)
    2. October (3)
    3. July (1)
    4. March (1)
    5. February (4)
  3. 2018 (52)
    1. December (2)
    2. November (4)
    3. October (2)
    4. September (4)
    5. August (4)
    6. July (7)
    7. June (7)
    8. May (6)
    9. April (5)
    10. March (3)
    11. February (6)
    12. January (2)
  4. 2017 (45)
  5. 2016 (25)
  6. 2015 (26)
  7. 2014 (6)
  8. 2013 (13)
  9. 2012 (6)